GlassScriptPhysician profile
Kayla Stoick
NPI 1427539626
$23,096.79
in general payments reported to CMS, 2019-2025
35 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,040 · 2022: $2,883 · 2023: $3,775 · 2024: $4,659 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $2,930 · Travel and Lodging: $789 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $340 · Education: $69.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,045.55 |
| Consulting Fee | $2,930.00 |
| Travel and Lodging | $789.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $340.00 |
| Education | $69.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,341.84 | 2021-2025 | |
| Janssen Biotech, INC. | $3,087.38 | 2021-2025 | Tremfya, Stelara, Remicade |
| Genentech USA, INC. | $2,663.07 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,787.06 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,343.94 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $1,267.37 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $1,152.13 | 2021-2025 | |
| Genzyme Corporation | $1,079.80 | 2022-2025 | |
| Lilly USA, LLC | $919.62 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $653.32 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $633.08 | 2024-2025 | Vowst, Zenpep |
| Qol Medical, LLC | $536.69 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $470.48 | 2022-2025 | Dupixent |
| Celgene Corporation | $467.22 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $408.51 | 2023-2025 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $380.38 | 2021-2025 | Ocaliva |
| Axonics, INC. | $208.33 | 2024 | Axonics, Bulkamid |
| Madrigal Pharmaceuticals | $185.45 | 2025 | Rezdiffra |
| Mirum Pharmaceuticals, INC. | $177.23 | 2024-2025 | Livmarli |
| Ironwood Pharmaceuticals, INC | $166.56 | 2021-2024 | Linzess |
| Amgen INC. | $156.29 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Ferring Pharmaceuticals INC. | $152.56 | 2022-2025 | Rebyota |
| Pfizer INC. | $135.19 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $117.76 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $116.97 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.55 | 2023-2024 | Cyltezo |
| Organon LLC | $90.00 | 2021-2022 | |
| Braintree Laboratories, INC. | $83.21 | 2021-2025 | Suflave |
| Celltrion USA INC. | $41.29 | 2025 | Vegzelma |
| Genentech, INC. | $39.16 | 2025 | |
| Nestle Healthcare Nutrition INC. | $33.21 | 2021-2022 | |
| Enterra Medical, INC. | $27.46 | 2025 | |
| Mylan Institutional INC. | $23.39 | 2023 | |
| Daiichi Sankyo INC. | $20.04 | 2022 | |
| Orphalan INC | $15.25 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Stoick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.